Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells

被引:0
|
作者
Mototsugu Oya
Masafumi Ohtsubo
Atsushi Takayanagi
Masaaki Tachibana
Nobuyoshi Shimizu
Masaru Murai
机构
[1] Keio University School of Medicine,Department of Urology
[2] Shinjuku-ku,Department of Molecular Biology
[3] Keio University School of Medicine,undefined
[4] Shinjuku-ku,undefined
来源
Oncogene | 2001年 / 20卷
关键词
renal cell carcinoma; TRAIL; NF-κB; IκBα; apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.
引用
收藏
页码:3888 / 3896
页数:8
相关论文
共 50 条
  • [41] Nuclear factor-κB activation in human testicular apoptosis
    Pentikäinen, V
    Suomalainen, L
    Erkkilä, K
    Martelin, E
    Parvinen, M
    Pentikäinen, MO
    Dunkel, L
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (01): : 205 - 218
  • [42] Mechanisms of resistance to TRAIL-induced apoptosis in cancer
    Lidong Zhang
    Bingliang Fang
    Cancer Gene Therapy, 2005, 12 : 228 - 237
  • [43] Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells
    A. Munshi
    T. McDonnell
    R. Meyn
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 46 - 52
  • [44] TRAIL-induced apoptosis of osteogenic sarcoma and breast cancer cells.
    Findlay, DM
    Bouralexis, S
    Atkins, GJ
    Hedi, L
    Hay, S
    Evdokiou, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S352 - S352
  • [45] Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells
    Piccioli, P
    Porcile, C
    Stanzione, S
    Bisaglia, M
    Bajetto, A
    Bonavia, R
    Florio, T
    Schettini, G
    JOURNAL OF NEUROSCIENCE RESEARCH, 2001, 66 (06) : 1064 - 1073
  • [46] TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention
    Manzoor Ahmad
    Yufei Shi
    Oncogene, 2000, 19 : 3363 - 3371
  • [47] eNOS protects prostate cancer cells from TRAIL-induced apoptosis
    Tong, X
    Li, HL
    CANCER LETTERS, 2004, 210 (01) : 63 - 71
  • [48] Inhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis
    Wu, P.
    Cheng, Y. W.
    Wang, J. Y.
    Zhang, X. D.
    Zhang, L. J.
    NEOPLASMA, 2014, 61 (02) : 136 - 143
  • [49] Polyphenol acertannin prevents TRAIL-induced apoptosis in human keratinocytes by suppressing apoptosis-related protein activation
    Lee, Chung Soo
    Janga, Eun-Ra
    Kim, Yun Jeong
    Seo, Seong Jun
    Choi, Sun Eun
    Lee, Min Won
    CHEMICO-BIOLOGICAL INTERACTIONS, 2011, 189 (1-2) : 52 - 59
  • [50] Penehyclidine prevents nuclear factor-κB activation in acute lung injury induced by lipopolysaccharide
    Li, Juan
    Li, Jun
    Zhang, Lei
    Huang, Yan
    Pan, Jian-Hui
    Chen, Kun-Zhou
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (09) : 1197 - 1205